Pharmacokinetics of nirmatrelvir/ritonavir and the drug-drug interaction with calcineurin inhibitor in renal transplant recipients

ConclusionsThe PK characteristics of nirmatrelvir/ritonavir vary greatly among renal transplant recipients. Factors including Ccr andCYP3A5 genotype were related to the in vivo exposure of nirmatrelvir/ritonavir. During the whole process before and after nirmatrelvir/ritonavir therapy, it is recommended to adjust the CNI basing on renal function to avoid CNI toxicity exposure.

http://link.springer.com/10.1007/s00228-024-03691-9

Source: European Journal of Clinical Pharmacology - May 1, 2024 Category: Drugs & Pharmacology Source Type: research